Healthcare Industry News: Bradley Pharmaceuticals
News Release - January 17, 2007
Bradley Pharmaceuticals Welcomes Alton Delane, Vice President, Business DevelopmentFAIRFIELD, N.J., Jan. 17 (HSMN NewsFeed) -- Bradley Pharmaceuticals, Inc. (NYSE: BDY ) today announced that Alton Delane has joined the Company as Vice President, Business Development. Mr. Delane will be responsible for maximizing Bradley's business development efforts, with a particular focus on acquisitions and licensing.
Mr. Delane brings Bradley over seven years experience in finance. Most recently, Mr. Delane served as Vice President, Healthcare Investment Banking for Raymond James and Associates, where he advised middle market pharmaceutical and healthcare service companies on mergers and acquisitions. Mr. Delane's expertise includes the branded and generic pharmaceutical as well as the drug delivery sectors.
In addition to his investment banking experience, Mr. Delane also served as a Lieutenant in the United States Navy and as an officer on the nuclear- powered submarine USS Billfish. Mr. Delane holds an MBA from Harvard Business School and a BS in Aerospace Engineering from the United States Naval Academy.
Bradley President and CEO, Daniel Glassman, stated, "The Bradley Management Team looks forward to working with Mr. Delane, an experienced professional in pharmaceutical mergers and acquisitions. His financial expertise, coupled with proven leadership skills, will be valuable as Bradley continues to execute the current phase of its strategic plan to in-license, develop and bring to market patent-protected brands."
Please visit Bradley Pharmaceuticals web site at: www.bradpharm.com
Bradley Pharmaceuticals common stock is listed on the NYSE under the symbol BDY.
Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty pharmaceutical company and markets to niche physician specialties in the U.S. and 38 international markets. Bradley's success is based upon strategically expanding from an Acquire, Enhance and Grow to an In-License, Develop and Bring to Market business model: In-license phase II and phase III drugs with long-term intellectual property protection; Develop these products and submit completed clinical studies to the FDA for NDA approvals and commercialization; Bring to Market these patent-protected brands to fill unmet needs and leverage Bradley's marketing and sales expertise to increase shareholder value. Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, OBGYN, respiratory and other internal medicine brands; and A. Aarons, which markets authorized generic versions of Doak and Kenwood therapies.
Bradley Pharmaceuticals will present at the Wachovia Securities Small and Mid-Cap Healthcare Conference, January 30, 2007, at 8:30 AM at the Langham Hotel in the Timberlay Room, Boston MA.
Bradley Pharmaceuticals will present at the Roth Capital Partners 19th Annual OC Conference, February 21, 2007, at 12 noon at the Ritz Carlton Laguna Niguel, CA.
Bradley Pharmaceuticals will present at the Raymond James & Associates 28th Annual Institutional Investors Conference, to be held at the Hyatt Regency Grand Cypress in Orlando, FL, March 4-7, 2007.
Safe Harbor for Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that Bradley expects, believes or anticipates will or may occur in the future, such as sales and earnings estimates, other predictions of financial performance, timing of payments on indebtedness, launches by Bradley of new products, market acceptance of Bradley's products, timing and repurchases of shares of common stock, and the achievement of initiatives to enhance corporate governance and long-term shareholder value. Forward-looking statements are based on Bradley's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond Bradley's control. These risks and uncertainties include Bradley's ability to: successfully acquire, develop, integrate or sell new products, including Veregen(tm) (f/k/a Polyphenon(r) E Ointment), Elestrin(tm) and the products incorporating the delivery systems to be developed by Polymer Science; estimate sales; comply with the restrictive covenants under its credit facility; refinance its credit facility, if necessary; access the capital markets on attractive terms or at all; favorably resolve the pending SEC informal inquiry and file required financial statements with the SEC in a timely manner; remediate its material weaknesses in its internal controls; maintain sales of its products; or effectively react to other risks and uncertainties described from time to time in Bradley's SEC filings, such as fluctuation of quarterly financial results, estimation of product returns, chargebacks, rebates and allowances, concentration of customers, reliance on third party manufacturers and suppliers, litigation or other proceedings (including the pending class action and shareholder derivative lawsuits), government regulation, stock price volatility and ability to achieve strategic initiatives to enhance long-term shareholder value. Further, Bradley cannot accurately predict the impact on its business of the approval, introduction, or expansion by competitors of generic or therapeutically equivalent or comparable versions of Bradley's products or of any other competing products. In addition, actual results may differ materially from those projected. Bradley undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Source: Bradley Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.